文献速递糖尿病

IONIS-GCGRRx 反义抑制胰高血糖素受体改善 2 型糖尿病且不增加肝糖原含量

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
PubMed 文献 · Diabetes Care · 2019-02-14

三项 2 期随机双盲研究评估 IONIS-GCGRRx(靶向胰高血糖素受体的反义寡核苷酸)在稳定二甲双胍治疗的 2 型糖尿病患者中的安全性和疗效。结果显示 IONIS-GCGRRx 显著降低 HbA1c,转氨酶呈剂量依赖性升高但低剂量多正常,且不增加肝糖原含量。

要点

  • IONIS-GCGRRx 每周皮下注射显著降低 HbA1c,呈剂量依赖性。
  • 转氨酶升高呈剂量依赖性,50 mg 剂量下多保持在正常参考范围内。
  • 100 mg 剂量未显著影响肝糖原含量,但显著增加肝脂质含量。

核心结论

  • IONIS-GCGRRx 是有效的肝胰高血糖素受体表达抑制剂,低周剂量联合二甲双胍可改善血糖控制。
  • 在测试的全剂量范围内 HbA1c 均显著降低,低剂量下转氨酶升高轻微。
  • 尽管胰高血糖素受体拮抗后糖原分解被抑制,IONIS-GCGRRx 并未增加肝糖原含量。

研究设计与样本

  • 三项 2 期随机双盲研究,纳入稳定二甲双胍治疗的 2 型糖尿病患者。
  • 患者每周皮下注射 IONIS-GCGRRx(50-200 mg)或安慰剂,疗程 13 或 26 周。

主要发现

  • 第 14 周 HbA1c 较安慰剂显著降低:200 mg 组 -2.0%,100 mg 组 -1.4%,安慰剂组 -0.3%(P < 0.001)。
  • 第 27 周 HbA1c 较安慰剂显著降低:75 mg 组 -1.6%,50 mg 组 -0.9%,安慰剂组 -0.2%(P < 0.001)。
  • 转氨酶呈剂量依赖性升高,低剂量时减弱,50 mg 剂量下多保持在正常参考范围内。
  • 第 14 周 100 mg 组肝糖原含量较安慰剂无显著变化(15.1 vs. -20.2 mmol/L,P = 0.093)。
  • 第 14 周 100 mg 组肝脂质含量较安慰剂显著增加(4.2 vs. -2.7%,P = 0.005),同时伴转氨酶升高。

临床怎么用

  • IONIS-GCGRRx 低周剂量联合二甲双胍可能改善 2 型糖尿病血糖控制。
  • 使用中需监测转氨酶,低剂量下转氨酶升高多轻微。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of IONIS-GCGRRx, a 2'-O-methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the underlying mechanism of liver transaminase increases in patients with type 2 diabetes on stable metformin therapy. RESEARCH DESIGN AND METHODS: In three phase 2, randomized, double-blind studies, patients with type 2 diabetes on metformin received weekly subcutaneous injections of IONIS-GCGRRx (50-200 mg) or placebo for 13 or 26 weeks. RESULTS: Significant reductions in HbA1c were observed after IONIS-GCGRRx treatment versus placebo at week 14 (-2.0% 200 mg, -1.4% 100 mg, -0.3% placebo; P < 0.001) or week 27 (-1.6% 75 mg, -0.9% 50 mg, -0.2% placebo; P < 0.001). Dose-dependent increases in transaminases were observed with IONIS-GCGRRx, which were attenuated at lower doses and remained mostly within the normal reference range at the 50-mg dose. There were no other significant safety observations and no symptomatic hypoglycemia or clinically relevant changes in blood pressure, LDL cholesterol, or other vital signs. At week 14, IONIS-GCGRRx 100 mg did not significantly affect mean hepatic glycogen content compared with placebo (15.1 vs. -20.2 mmol/L, respectively; P = 0.093) but significantly increased hepatic lipid content (4.2 vs. -2.7%, respectively; P = 0.005) in the presence of transaminase increases. CONCLUSIONS: IONIS-GCGRRx is a potent inhibitor of hepatic glucagon receptor expression with a potential to improve glycemic control at low weekly doses in combination with metformin. Significant reductions in HbA1c occurred across the full-dose range tested, with minimal transaminase elevations at lower doses. Furthermore, novel results suggest that despite inhibition of glycogenolysis after GCGR antagonism, IONIS-GCGRRx did not increase hepatic glycogen content.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Morgan ES, Tai LJ, Pham NC, et al. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy. Diabetes Care. 2019. PMID: 30765435. doi:10.2337/dc18-1343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。